Human papillomavirus 66 (HPV66) is a mucosotropic type of Alphapapillomavirus with a circular double-stranded DNA genome. It is considered a high-risk or probable high-risk human papillomavirus because persistent infection may contribute to carcinogenesis.
Virology & Oncogenic Mechanisms
HPV66 shares genomic organisation with other high‑risk papillomaviruses. Its approximately 8 kb genome encodes early proteins E1–E7 and late structural proteins L1–L2. Oncoproteins E6 and E7 can bind to the p53 and retinoblastoma tumour suppressor proteins, but their transforming activity appears weaker than that of HPV16 or HPV18. The virus infects basal keratinocytes via microabrasions, initially maintaining its genome as a low‑copy episome. Viral replication is linked to epithelial differentiation; integration of viral DNA into the host genome with up‑regulated E6/E7 expression can support malignant progression. Although HPV16 and HPV18 account for most HPV‑related cancers, certain less prevalent types such as 66 are classified as high‑risk by some agencies because they have been detected in high‑grade lesions and cancers.
Clinical Impact and Prevention
HPV66 infection is relatively uncommon. It has been detected in low‑grade and high‑grade squamous intraepithelial lesions and occasionally in invasive cervical cancer, but its oncogenic potency is lower than that of more prevalent high‑risk types. Current prophylactic vaccines do not include HPV66, so prevention depends on limiting transmission and early detection. Regular cervical screening with Pap cytology and high‑risk HPV DNA testing is important because assays for “other high‑risk” types often detect HPV66. Most infections are transient and cleared by the immune system. Safer sexual practices and smoking cessation help reduce the likelihood of persistent infection. HPV66 is considered a probable high‑risk papillomavirus that can contribute to cervical neoplasia, although it is much less prevalent and less oncogenic than HPV16 or HPV18. Screening and risk‑reducing behaviours remain key for management. Related Terms: HPV53, HPV68, Probable high‑risk HPV, Cervical screening, E6 protein